We Asked Claude AI Where Ripple (XRP) Goes If ETF Inflows Hit $5 Billion
Ripple ( CRYPTO: XRP ) ETFs continue to draw institutional inflows despite its price trading in a na…
247wallst.com
NVAX(NVAX)
NVAX
Next earnings: Aug 5, 2026 · Before open
Signal
Mixed1↑1↓
PRICE
Prev Close
9.35
Open
9.13
Day Range8.93 – 9.33
8.93
9.33
52W Range6.13 – 11.97
6.13
11.97
50% of range
VOLUME & SIZE
Avg Volume
4.7M
FUNDAMENTALS
P/E Ratio
-16.2x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
Quick Read
Trend—Insufficient MA data
Momentum
NEUTRAL
rev -52% · 85% gross marginValuation
FAIR
P/E not availableHealth
WEAK
CR 2.5 · FCF negativeLean Bearish
Key MetricsTTM
Market Cap$1.49B
Revenue TTM$596.34M
Net Income TTM-$87.83M
Free Cash Flow-$97.17M
Gross Margin84.6%
Net Margin-14.7%
Operating Margin-11.2%
Return on Equity89.7%
Return on Assets-8.4%
Debt / Equity-2.04
Current Ratio2.48
EPS TTM$-0.54
Alpha SignalsView Intelligence →
Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.
Health Radar
4 strong2 concern
59/100Liquidity
2.48Strong
Leverage
-2.04Strong
Coverage
-5.6xConcern
ROE
89.7%Strong
ROIC
-9.5%Concern
Cash
$241MStrong
ANALYST COVERAGE23 analysts
BUY
▲ +98.7%upside to target
L $11.00
Med $18.00consensus
H $25.00Stock Health
Composite Score
5 of 5 signals bullish
10/10
Technicals
●
✓RSI RangeRSI 55 — Bullish momentum
Volume
●
✓Volume FlowAccumulation — institutional buying
Fundamentals
●
✓Last EarningsBeat estimates
●
✓Analyst ConsensusBuy
●
✓LiquidityCurrent Ratio 2.48 — healthy liquidity
Upcoming Events
EEarnings ReportMay 17, 2026
Tomorrow
DEx-Dividend DateAug 14, 2026
In 90 days
PDividend PaymentAug 31, 2026
In 107 days
FinancialsFull statements →
Technicals
Technical SetupBULLISH
Technicals →Trend
▲ UptrendGolden Cross · 50D leads 200D by 8.1%
+0.9% vs SMA 50 · +9.1% vs SMA 200
Momentum
RSI54.9Neutral territory
MACD+0.25Above zero — bullish momentum · expanding
Market Position
Price Levels
52W High
$11.97+32.1%
Current
$9.06
EMA 50
$8.87-2.1%
EMA 200
$8.26-8.8%
52W Low
$6.13-32.3%
52-Week RangeMid-range
$6.1350th %ile$11.97
Squeeze SetupVolume-based
Moderate Squeeze SetupAccumulation pattern present — more buying days than selling over the past 20 sessions. Volume conditions support gradual price improvement.
20-Day Money Flow
Acc days:4
Dist days:3
Edge:+1 acc
Volume Context
Avg Vol (50D)4.4M
Recent Vol (5D)
6.1M+39%
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
Earnings & Analysts
ANALYST ESTIMATES
Consensus of 7 analysts
Analyst revisions:EPS↑ Revised UpRevenue↑ Revised Up
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2025 | $1.1B $680.6M–$1.1B | — | $2.23 | — | ±45% | High7 |
FY2026(current) | $410.0M $317.7M–$473.8M | ▼ -61.5% | -$0.47 | — | ±50% | High7 |
FY2027 | $258.5M $140.4M–$371.1M | ▼ -37.0% | -$0.25 | — | ±50% | High7 |
Range confidence:Tight (high)ModerateWide (low)
🔥Beat 7 consecutive quarters
Earnings HistoryNVAX
Last 8Q
+192.3%avg beat
Beat 7 of 8 quartersMissed 1↓ Estimates falling-40%
Q3'24
+13%
Q4'24
+32%
Q1'25
+313%
Q2'25
+986%
Q3'25
+43%
Q4'25
+117%
Q1'26
+76%
Q2'26
Beat
Miss
Estimate
Deeper color = bigger beat/miss
* Negative EPS shown at reduced heightAnalyst Activity
All ratings →No recent activity
Bank of America Sec…Underperform → Neutral
May 10
UPGRADE
WedbushNeutral
Aug 9
DOWNGRADE
Wells FargoOverweight
Aug 9
UPGRADE
Raymond JamesMarket Perform → Outperform
Aug 9
UPGRADE
RBC CapitalSector Perform
Aug 9
DOWNGRADE
NeedhamHold
Aug 9
DOWNGRADE
Telsey AdvisoryMarket Perform
Aug 9
DOWNGRADE
Evercore ISINeutral
Aug 9
DOWNGRADE
B. Riley SecuritiesBuy → Reduce
Mar 12
DOWNGRADE
J.P. MorganBuy
Sep 22
DOWNGRADE
CFRABuy
Jun 8
UPGRADE
Financials
INSTITUTIONAL OWNERSHIP
1
SHAH CAPITAL MANAGEMENT
14.8M▲2
BlackRock, Inc.
12.8M▼3
Sanofi
6.9M—4
UBS Group AG
4.5M▼5
Allianz Asset Management GmbH
1.9M▼6
NORTHERN TRUST CORP
1.5M▲7
TSP Capital Management Group, LLC
1.4M▲8
VANGUARD FIDUCIARY TRUST CO
1.1M▲News & Activity
NVAX News
20 articles · 4h ago
iFabric Q1 Earnings Call Highlights
marketbeat.com
Interfor Q1 Earnings Call Highlights
marketbeat.com
Intermap Technologies Q1 Earnings Call Highlights
marketbeat.com
Keyera Q1 Earnings Call Highlights
marketbeat.com
K92 Mining Q1 Earnings Call Highlights
marketbeat.com
KP Tissue Q1 Earnings Call Highlights
marketbeat.com
DexCom Maps G8 Launch, Coverage Expansion and Double-Digit Growth at Investor Day
marketbeat.com
Constellation Brands: Consumer Weakness Creates A Buying Opportunity
seekingalpha.com
Nextech3D.ai launches AI event marketplace targeting $1T industry - ICYMI
proactiveinvestors.com
Here's Berkshire Hathaway's new stock trades after Warren Buffett's exit
finbold.com
Playtika's Strong Guidance Signals A Real Turn (Rating Upgrade)
seekingalpha.com
Tech Heads Accompany Trump on China Trip
youtube.com
Sezzle And Pagaya Partner Up To Expand BNPL Operations
seekingalpha.com
Schneider Electric: Long Reinvestment Runway Across Electrification
seekingalpha.com
Cellebrite: Positive Q1 Results, But There Is Room For Margin Improvements
seekingalpha.com
Nebius Group, Cisco Systems, Micron Technology And More: 5 Stocks Investors Couldn't Stop Buzzing About This Week
benzinga.com
Prediction: NuScale Power Stock Is a Buy Before 2027 Due to This $1.75 Trillion Opportunity
fool.com
QQQI: The Income Feels Good, But The Bear Market Won't
seekingalpha.com
Realty Income: Raised Guidance, Higher Growth Expectations Reinforces The Bull Case For Income Investors
seekingalpha.com
About
novavax, inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. our recombinant nanoparticles and matrix-m™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. product pipeline our product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for respiratory syncytial virus ("rsv"), seasonal influenza, pandemic influenza, and ebola virus ("ebov"). we have additional preclinical-stage programs for a variety of infectious diseases. corporate overview novavax is headquartered in gaithersburg, maryland with additional facilities in rockville, maryland and uppsala, sweden. novavax is traded on the nasdaq stock market under the symbol nvax and employs over 300 individuals dedicated to developing novel vaccines to address infectious disease.
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Stanley Erck
Website
Robert WalkerEVice President and Head of Research & Development
Luis SanayVice President of Investor Relations
Ian J. WatkinsExecutive Vice President & Chief Human Resources Officer
Peers— Health Care(7 companies)
Screen sector →| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
NVAX◀ | $9.06 | +0.00% | $1.5B | — | +6469.4% | — | 1500 |
| $66.13 | -5.07% | $13.0B | — | +12626.1% | -14525.8% | 1500 | |
| $94.92 | -3.79% | $12.6B | — | +3288.2% | -4239.0% | 1500 | |
| $523.69 | -3.00% | $12.1B | — | +43205.3% | -3008.0% | 1500 | |
| $227.72 | -1.30% | $11.7B | — | +6554.5% | -2868.8% | 1500 | |
| $57.90 | -0.86% | $11.2B | 50.3 | +1459.3% | 147.7% | 1500 | |
| $76.67 | -3.79% | $10.8B | — | +2325815.3% | -19.7% | 1500 | |
| Sector avg | — | -2.54% | — | 50.3 | +342774.0% | -4085.6% | 1500 |